Regencell Bioscience (NASDAQ:RGC) Stock Price Up 17.9% – Time to Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) shot up 17.9% during mid-day trading on Thursday . The stock traded as high as $15.34 and last traded at $15.34. 173,825 shares were traded during mid-day trading, a decline of 98% from the average session volume of 7,760,122 shares. The stock had previously closed at $13.01.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Trading Up 22.5%

The company has a 50 day moving average of $14.96.

Institutional Trading of Regencell Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of RGC. Greenfield Savings Bank acquired a new position in Regencell Bioscience during the second quarter valued at approximately $187,000. Y Intercept Hong Kong Ltd bought a new position in shares of Regencell Bioscience in the second quarter valued at $222,000. XTX Topco Ltd bought a new stake in Regencell Bioscience during the third quarter worth $598,000. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience in the second quarter valued at $768,000. Finally, Squarepoint Ops LLC bought a new position in shares of Regencell Bioscience in the 2nd quarter valued at about $1,701,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.